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Phosphorylation of IkBs—the cytoplasmic inhibitors of the NF-kB transcription factors—is the key event which triggers
activation of the NF-kB cascade. Signal-mediated phosphorylation of IkBa is mediated by a multiprotein complex, the IkB
kinase (IKK) complex, which is composed of at least three identified subunits. Two of these polypeptides, IKKa and IKKb, also
known as IKK1 and IKK2, are the catalytic subunits of the kinase complex and phosphorylate IkBa and IkBb. The third
component, NEMO/IKKg, does not exhibit kinase activity, but rather constitutes a regulatory subunit. In the present study,
C-terminal truncated forms of IKKg—DC-IKKg 306 and DC-IKKg 261—were stably expressed in the myeloid cell line U937
by retroviral-mediated gene transfer. Overexpression of DC-IKKg resulted in a reduction in IKK kinase activity in vitro, a
subsequent decrease in NF-kB DNA binding activity, and inhibition of chemokine gene induction in response to TNFa
stimulation or paramyxovirus infection. This study demonstrates the efficacy of DC-IKKg as a repressor of IKK signaling and
NF-kB activation and suggests a potential gene therapy approach to limit chronic inflammation due to chemokine hyperac-
tivation. © 2001 Academic Press
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The NF-kB/Rel family of transcription factors plays an
important role in immunity, stress response, and apopto-
sis by regulating the expression of numerous cellular
and viral genes (Ghosh et al., 1998; Pahl, 1999). NF-kB
xists as homo- and heterodimers of related proteins,
hich share a conserved DNA-binding and dimerization
omain, called the Rel homology domain. The major
F-kB complexes are composed of either p65 (RelA) and
p50 or c-Rel and p50 subunits. In unstimulated cells, the
NF-kB dimers are maintained in an inactive form in the
cytoplasm by the inhibitory proteins IkB which include
IkBa, IkBb, and IkBe (Baldwin, 1996). A variety of stimuli
such as inflammatory cytokines (TNFa, IL-1b), mitogens,
acterial lipopolysaccharide, viral products, and double-
tranded RNA induce IkB phosphorylation on serine res-
idues in the amino-terminal signal response domain (Ka-
rin and Ben-Neriah, 2000). Upon phosphorylation, IkB
proteins are multiubiquinated and targeted to the 26S
proteasome for degradation, leading to its dissociation
from the NF-kB DNA-binding subunits (Hatada et al.,
2000; Scherer et al., 1995). Released NF-kB translocates
nto the nucleus where it activates a multitude of target
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422enes. Phosphorylation of IkBs is thus a key event which
triggers the NF-kB activation cascade.
Signal-mediated phosphorylation of IkBa is mediated
y a multiprotein complex called the IkB kinase (IKK)
omplex, composed of three identified subunits (Karin,
999). Two of these polypeptides, IKKa and IKKb (also
nown as IKK1 and IKK2), are the catalytic subunits of the
inase and phosphorylate IkBa and IkBb (DiDonato et
l., 1997; Regnier et al., 1997; Rothwarf et al., 1998; Uhlik
t al., 1998; Woronicz et al., 1997; Zandi and Karin, 1999;
andi et al., 1997). The unique and essential in vivo roles
of IKKa and IKKb in the regulation of NF-kB activity were
demonstrated using ikk knockout mice (Karin and Ben-
eriah, 2000). ikka-deficient mice exhibit perinatal lethal-
ity within 30–60 min after birth and display skeletal de-
formations and epidermal thickening, suggesting that the
primary defect occurs in epidermal differentiation (Hu et
al., 1999; Li et al., 1999a; Takeda et al., 1999). Surprisingly,
activation of the IKK complex and NF-kB induction in
response to pro-inflammatory stimuli is normal in
ikka2/2 mice. In contrast, the phenotype of ikkb-defi-
ient mice is embryonic lethality due to massive liver
poptosis (Li et al., 1999b,e; Tanaka et al., 1999). More-
ver, NF-kB activation is completely defective in ikkb-
deficient embryonic fibroblasts in response to TNF-a or
IL-1, reflecting the critical role of IKKb in NF-kB induction.
The third component of the IKK complex, IKKg, also
nown as FIP3 (Ad E3–14.7K interacting protein), IKKAP1
IKK complex associated protein-1), and NEMO (NF-kB
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423IKKg/NEMO MUTANTS DISRUPT IKK SIGNALING AND NF-kB ACTIVATIONessential modulator), does not exhibit kinase activity, but
rather constitutes a regulatory subunit (Mercurio et al.,
1999; Rothwarf et al., 1998; Yamaoka et al., 1998). IKKg
functional activity has been characterized by several
different approaches. Inhibition of IKKg expression using
n antisense strategy resulted in decreased IKK activity
nd NF-kB activation (Rothwarf et al., 1998). Genetic
complementation of a HTLV-1 Tax-transformed rat fibro-
blast cell line that was unresponsive to NF-kB inducers
ith a cDNA encoding NEMO restored NF-kB activation
Yamaoka et al., 1998). IKKg-deficient mice were gener-
ated and embryonic fibroblasts from these animals lack
detectable NF-kB activity in response to TNFa, IL-1, LPS,
nd poly(IC); these mice die at E12.5–E13.0 from severe
iver damage due to apoptosis. Furthermore, female mice
eterozygous for IKKg deficiency develop a dermatopa-
hy characterized by keratinocyte hyperproliferation, skin
nflammation, hyperkeratosis, and increased apoptosis,
imilar to incontinentia pigmenti (IP), a human genoder-
atosis (Makris et al., 2000; Rudolph et al., 2000;
chmidt-Supprian et al., 2000). Biopsies and cells from IP
atients exhibit defective IKKg expression but normal
expression of IKK catalytic subunits. This unique self-
limiting disease, the first to be genetically linked to the
IKK signaling pathway, is dependent on X-chromosome
inactivation (Smahi et al., 2000). Overexpression of wild-
type IKKg also induces apoptosis and downregulates
both basal and TNFa-induced NF-kB activity (Ye et al.,
2000). Recent studies have proposed that IKKg partici-
ates in IKK complex activation through its interactions
ith IKKa and IKKb subunits and with upstream activa-
ors such as RIP or NIK (NF-kB-inducing kinase) (Li et al.,
1999c; Ye et al., 2000). Interestingly, physical interaction
of IKKg with HTLV-1 Tax oncoprotein constitutively acti-
vates IKK catalytic subunits, thus bypassing the require-
ment for engagement of upstream activators (Chu et al.,
1999; Harhaj et al., 2000; Harhaj and Sun, 1999; Jin et al.,
1999).
The use of IKKg/NEMO mutants has also provided
information about the role of IKKg in IKK and NF-kB
ctivation. Expression of an N-terminal deletion mutant
amino acids 134–419) produced only marginal effects on
KK activity, whereas expression of a C-terminal mutant
amino acids 1–300) inhibited TNFa-induced IKK activa-
ion (Rothwarf et al., 1998). Recent structure–function
nalysis of IKKg revealed that the N-terminal domain is
esponsible for interactions with IKKa and IKKb; the
central domain (aa 201–319) constitutes the IKKg self-
association domain and mediates the RIP interaction
whereas both the amino- and the carboxyl terminal parts
are required for efficient apoptosis (Ye et al., 2000). To-
gether these studies indicate that IKKg/NEMO plays a
entral role in the integration of signaling pathways con-
erging on the IKK complex (Israel, 2000).To further characterize the role of IKKg in cellular
signaling and NF-kB regulation, two C-terminal truncatedforms of IKKg—DC-IKKg (1–306) and DC-IKKg (1–261)—
ere generated. In DC-IKKg 306, the distal, C-terminal
leucine zipper was deleted, while DC-IKKg 261 disrupted
he two C-terminal leucine zippers. These mutants of
KKg were transduced into myeloid U937 cells by retro-
viral-mediated gene transfer and their effects on the
functional activity of the IKK complex were evaluated in
terms of IKK activity, NF-kB DNA binding, and inducibility
f downstream chemokine genes.
RESULTS
table expression of IKKg C-terminal deletion
mutants
Two flag-tagged C-terminal deletion mutants of IKKg
were constructed that lacked either the C-terminal
leucine zipper domain (DC-IKKg 306) or the two last
leucine zipper domains (DC-IKKg 261) (Fig. 1A). Stable
expression of IKKg mutants was achieved in myeloid
937 cells using retroviral gene transfer. The retroviral
ector AP-2 (Galipeau et al., 1999) is a VSV G protein
pseudotyped vector expressing GFP, downstream of an
internal ribosome entry site (IRES). This construct per-
mits the expression of a bicistronic mRNA encoding both
IKKg and GFP, thus ensuring the expression of both
roteins and facilitating the selection of transfected cells
y cell sorting. Control U937 cells transduced with the
etrovector AP-2 alone were designated U-AP2. Cells
ransduced with retrovector particles carrying the DC-
IKKg 306 and DC-IKKg 261 mutants were named U-306
nd U-261, respectively. As shown in Fig. 1B, U-261 and
-306 cells overexpress the respective DC-IKKg proteins
elative to the doublet of endogenous IKKg. With U-306
cells, a peptide was also detected that migrated at ap-
proximately 26 kDa and may represent a proteolytic
cleavage product of Flag-DC-IKKg, since it was recog-
ized by IKKg antibody but not by anti-Flag antibody.
Although transduction efficiencies ranging from 70 to
90% were routinely achieved for viruses containing DC-
IKKg 306 and DC-IKKg 261 as determined by FACS anal-
ysis, no expression of full-length IKKg was detected in
the 293GPG packaging cells. Based on previous studies,
we concluded that stable expression of wild-type IKKg
induced apoptosis in the packaging cells, as demon-
strated for 293 cells (Ye et al., 2000).
Composition of the IKK complexes in U-261 and U-
306 cells
The capacity of truncated IKKg to associate with IKK
subunits was evaluated by coimmunoprecipitation anal-
ysis using anti-IKKa, anti-IKKg, and anti-Flag antibodies.
s expected, anti-IKKa and anti-IKKg immunoprecipi-
tated endogenous IKKa in all four cell lines tested (Fig.
2A, lanes 1–8). Immunoprecipitation of endogenous IKKa
or overexpressed Flag-tagged DC-IKKg also revealed
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424 LE PAGE ET AL.that IKKa interacted with DC-IKKg (Fig. 2C, lanes 3, 4),
and reciprocally anti-Flag coprecipitated IKKa (Fig. 2A,
lanes 11 and 12). Overexpression of DC-IKKg mutants did
ot affect the endogenous IKKa expression level (see
lso Fig. 2A, lanes 16–19), but more importantly, DC-IKKg
mutants were able to associate with endogenous IKKa.
Precipitation of the IKK complex with the anti-IKKa anti-
odies also precipitated endogenous IKKg from control
and DC-IKKg expressing cells (Fig. 2B, lanes 1–4), indi-
ating that DC-IKKg did not interfere with the association
f the endogenous IKKg with the IKK complex. Anti-IKKa
and anti-IKKg antibodies also immunoprecipitated an
FIG. 1. Retroviral-mediated expression of DC-IKKg in U937 cells. (A)
Schematic representations of the retrovector AP2 and IKKg. AP2 ret-
ovector serves as a template for the coexpression of DC-IKKg and a
reen fluorescent protein (GFP). The presence of a gene encoding for
FP, downstream of an internal ribosome entry site (IRES), allows the
xpression of a bicistronic mRNA containing both the target gene and
he GFP. MCS, multiple cloning site. The relative positions of leucine
ippers (LZ) of IKKg are shown in the schematic of wild-type IKKg. The
deletions for DC-306 and DC-261 are shown. (B) Expression of the
C-IKKg. U937 cells were transduced with Flag-DC-IKKg retrovirus and
expression of endogenous and exogenous IKKg was analyzed by
immunoblot using the anti-IKKg antibody (top) or the anti-Flag antibody
(bottom). The relative positions of IKKg and DC-IKKg are shown by
rrows. The position of prestained molecular size markers is shown on
he right.KKg doublet (Fig. 2B, lanes 1–8, migrating just below the
IgG complex), whereas immunoprecipitation with anti- oFlag antibody failed to coprecipitate endogenous IKKg
(Fig. 2B, lanes 9–12), indicating that the carboxy-terminal
100 aa was required for homotypic dimerization of the
IKKg subunit. The specificity of immunoprecipitation was
onfirmed using control antiserum, which failed to immu-
oprecipitate IKKa or IKKg (Fig. 2, lanes 13–15). In addi-
tion, immunoblot analysis performed using whole cell
extracts (WCE) showed that the endogenous IKKg was
expressed in both U-261 and U-306 cell lines (Fig. 2,
lanes 16–19).
IKK activity is inhibited in U-261 and U-306 cell lines
The inhibitory effect of DC-IKKg 306 and DC-IKKg 261
on IKK activity was next analyzed by in vitro kinase
assays in control and DC-IKKg expressing cells. After
timulation with TNFa for 5 min or with Sendai virus for
h, the IKK complex was immunoprecipitated using an
nti-IKKa antibody and kinase activity was determined by
hosphorylation of the GST-IkBa (aa 1–55) substrate.
TNFa stimulation increased IKK activity 5- to 10-fold in
oth U937 and U-AP2 cells (Fig. 3A, compare lanes 1 and
, 5 and 6, and 9 and 10), as detected following immu-
oprecipitations with either anti-IKKa or IKKg. In contrast,
nduced kinase activity was decreased by more than 70%
n U-261 and U-306 cells, compared to U937 or U-AP2
ells (Fig. 3A, compare lanes 5 and 6 with 7 and 8 and 9
nd 10 with 11 and 12). No kinase activity was observed
hen GST-IkBa 2ND4 was used as substrate (Fig. 3A,
lanes 17–20), demonstrating the specificity of the kinase
for Ser 32 and Ser 36. Furthermore, no kinase activity
was detected in IKK complexes immunoprecipitated with
anti-Flag antibody, demonstrating the dominant inhibitory
effect of DC-IKKg on IKK activity (Fig. 3A, lanes 13–16).
Similarly, the greater than 10-fold stimulation of IKK ac-
tivity by Sendai virus (Fig. 3B, lanes 5 and 6) was ablated
by coexpression of DC-IKKg in U-261 and U-306 cells
Fig. 3B, lanes 7 and 8).
kBa degradation in DC-IKKg expressing cell lines
Phosphorylation of IkBa and IkBb by the IKK complex,
ollowed by ubiquitination and proteasome-mediated
egradation, are key steps in the regulation of NF-kB
ctivation. The results obtained with the in vitro kinase
nalyses suggested that expression of the DC-IKKg mu-
ants may impair the signaling pathway leading to IkB
egradation and NF-kB induction in response to TNFa
stimulation or Sendai virus infection. As shown in Fig. 4A,
IkBa protein was degraded by 15 min after treatment and
reappeared within 60 min in U937 or U-AP2 cell lines
(Fig. 4A, lanes 1, 2, 5, 6, 9, 10, 13, and 14). In Sendai virus
infected cells, IkBa degradation occurred more slowly at
3 h and the resynthesis of IkBa was observed after 6 h
of virus infection (Fig. 4A, lanes 17, 18, 21, 22, 25, 26, 29,
and 30). In DC-IKKg expressing cells IkBa protein turn-
ver was only slightly affected by DC-IKKg expression
4
a
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425IKKg/NEMO MUTANTS DISRUPT IKK SIGNALING AND NF-kB ACTIVATION(less than twofold) following TNF treatment (Fig. 4A,
lanes 3, 4, 7, 8, 11, 12, 15, and 16) or Sendai virus infection
(Fig. 4A, lanes 19, 20, 23, 24, 27, 28, 31, and 32). Following
TNFa stimulation in the presence of cycloheximide (Fig.
B), only slightly more IkBa was detected in the U-306
cell line compared to control U937 or U-AP2 cell lines
FIG. 2. Composition of IKK complex in DC-IKKg expressing U937 cells
(200 mg) were immunoprecipitated (IP) with 1 mg of an anti-IKKa, 1 m
immune complexes were separated on 10% SDS–PAGE transferred to m
(A) IKKa, (B) IKKg, or (C) Flag epitope as indicated. The positions of IKK
Similar results were observed in two independent experiments.
FIG. 3. Inhibition of IKK kinase activity in DC-IKKg U937 cells. U937,
A) or 3 h with Sendai virus (80 HAU/ml) (in B). Total protein extracts w
rabbit nonimmune serum (NI). The immune complexes were monitore
32substrate in the presence of [g- P]ATP. Phosphoproteins were resolved by SD
of IkBa is shown. Similar results were observed in three independent experi(Fig. 4B, lanes 8 and 12, compared to lanes 5 and 7
and 9 and 11), indicating that DC-IKKg expression had
only limited effect on IkBa degradation. In the same
experiments, IkBb turnover was also examined; at 3 h
after TNFa stimulation (Fig. 4C, lanes 13–16) and at 6 h
fter virus infection (Fig. 4C, lanes 25–28) IkBb turn-
cells, U-AP2, U-261, or U-306 cells were lysed and total protein extracts
anti-IKKg or 2 mg anti-Flag antibody, or nonimmune serum (NI). The
ne and successively immunoblotted with 1 mg/ml of antibodies against
, and DC-IKKg are indicated as the IgG band. WCE, whole cell extract.
, or DC-IKKg cells were stimulated for 5 min with TNFa (10 ng/ml) (in
pared and immune precipitated with anti-IKKa, anti-IKKg, anti-Flag, or
KK activity in vitro using GST-IkBa (aa 1–55) or GST-IkBa2ND4 as a. U937
g of an
embraU-AP2
ere pre
d for IS–PAGE and visualized by autoradiography. The phosphorylated form
ments.
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426 LE PAGE ET AL.over was detected, as previously described for other
cell types (Weil et al., 1997). However, no effect of
C-IKKg expression was observed on the kinetics of
FIG. 4. IkBa degradation kinetic in U937 cells expressing DC IKKg.
NFa (10 ng/ml) or Sendai virus (SeV, 80 HAU/ml) for the indicated times
(A) a monoclonal anti-IkBa antibody or (C) with a polyclonal anti-IkBb
retreatment with or without cycloheximide (CHX 50 mg/ml) for 30 min.
antibody. Expression of DC-IKKg was detected using a monoclona
xperiments.IkBb degradation, despite high-level expression of
DC-IKKg (Fig. 4C).
Nnhibition of NF-kB-dependent IkBa gene activation
Following phosphorylation and degradation of IkB,
7 cells and U-AP2 or DC-IKKg transduced cells were stimulated with
extracts were prepared, subjected to 10% SDS–PAGE, and probed with
ody. (B) Cells were stimulated with TNFa (10 ng/ml) for 60 min, after
kBa was determined by immunoblotting using a monoclonal anti-IkBa
lag antibody. Similar results were observed in three independent(A) U93
. Total
antib
Total IF-kB dimers translocate into the nucleus, bind to kB
sites, and transactivate the NF-kB-dependent down-
bp
U
w
5
m
1
w
a
E
o
c
7
t
I
U
2
R
a
t
f
a
s
o
a
g
p
g
m
a
m
t
t
p
M
n
d
427IKKg/NEMO MUTANTS DISRUPT IKK SIGNALING AND NF-kB ACTIVATIONstream targets. Since the IkBa gene contains NF-kB
inding sites in its promoter, NF-kB is able to autoregu-
late the transcription of its own inhibitor (Algarte et al.,
1999). To examine the activation of the IkBa gene, mRNA
from DC-IKKg expressing cells was analyzed by RNase
rotection assay (RPA) after stimulation for 1 h with TNFa
or for 4 h with Sendai virus. TNF treatment increased the
level of IkBa mRNA approximately 10-fold in U937 and
-AP2 cells (Fig. 5A, compare lanes 1 and 2 and 5 and 6)
hile virus infection increased IkBa mRNA by about
-fold (Fig. 5A, lanes 9 and 10). The amount of TNFa- or
virus-induced IkBa mRNA was decreased in the DC-IKKg
expressing cells, about 2-fold in U-261 and 4-fold in
U-306 compared to U937 or U-AP2 cells (Fig. 5A, lanes 7
and 8 and 11 and 12). To confirm this effect on IkBa
transcription, 293GPG packaging cell lines stably ex-
pressing DC-IKKg were transfected with the IkBa pro-
oter–luciferase reporter constructs (Algarte et al.,
999). As shown in Fig. 5B, IkBa reporter gene activity
as decreased more than 50% in 293GPG/DC-IKKg 306
nd 293GPG/DC-IKKg 261 expressing cells, compared to
293GPG or 293GPG/AP2 cells. Furthermore, no signifi-
cant luciferase activity was detected in cells transfected
with the IkBa promoter containing a mutated kB1 site
(Algarte et al., 1999), demonstrating the absolute require-
ment of this site for IkBa promoter activation (Fig. 5B).
MSA analyses further demonstrated that the inhibition
f IkBa promoter activity, observed in U-306 and U-261
ells, correlated with decreased NF-kB DNA-binding ac-
tivity to the kB1 site (Fig. 5C, compare lanes 5 and 6 with
and 8 and 9 and 10 with 11 and 12). The specificity of
he NF-kB complex—assessed by competition with un-
labeled oligonucleotides and supershift analysis with
subunit specific antibodies—identified the major binding
activity as a p50/p65 heterodimer (data not shown).
These results indicate that expression of DC-IKKg inhib-
ited inducer-mediated activation of NF-kB-dependent
IkBa gene expression.
nhibition of chemokine gene activation by DC-IKKg
expression
Stimulation of myeloid cells by viruses or by pro-
inflammatory cytokines leads to the expression of imme-
diate early response genes, including those encoding for
chemokines, which promote cellular recruitment to the
sites of infection. To examine the effect of DC-IKKg on
chemokine gene expression, mRNA analysis was per-
formed by RPA in U937 cells and DC-IKKg expressing
cells following stimulation with TNFa or Sendai virus for
2 and 8 h, respectively. TNFa stimulation of U937 and
-AP2 increased the levels of IL-8 mRNA more than
0-fold and to a lesser extent induced MIP-1a, MIP-1b,
ANTES, and IP-10 mRNA (Fig. 6A). In TNFa-stimulatedU-306 and U-261 cells, levels of IL-8 mRNA were de-
creased 3- to 4-fold, compared to levels in U937 andU-AP2. Following virus infection, MIP-1a, MIP-1b, IP-10,
and RANTES mRNA levels were induced from 20- to
70-fold in U937 and U-AP2 cells, whereas in DC-IKKg
expressing cells, chemokine mRNA levels were reduced
to 5- to 20-fold induction, overall representing a 3- to
4-fold inhibition. These results demonstrate a significant
inhibitory effect of DC-IKKg expression on TNFa-induced
IL-8 expression and virus-induced MIP-1a, MIP-1b, IP-10,
and RANTES mRNA levels in myeloid cells. EMSA anal-
yses further demonstrated that the reduction in mRNA
expression in DC-IKKg expressing cells correlated with
n inhibition of NF-kB DNA binding to the NF-kB site of
he RANTES promoter (Fig. 6B, lanes 5–12). The speci-
icity of the NF-kB complex was assessed as above and
the protein–DNA complex was identified as p50/p65
(data not shown). Together, these results demonstrate
that expression of dominant negative IKKg inhibits the
ctivation of NF-kB-dependent chemokine gene expres-
ion.
DISCUSSION
The NF-kB transcription factor is activated by many
pathogens and physiological factors, including viral and
bacterial infections, inflammatory cytokines, and cellular
injury. This activation leads to the coordinated expres-
sion of many genes that encode cytokines and chemo-
kines involved in amplification and perpetuation of the
immune response. NF-kB therefore constitutes an obvi-
us target for new types of therapeutic treatments aimed
t the signaling pathways controlling these inflammatory
enes. Inhibitors of NF-kB such as glucocorticoids or
roteasome inhibitors decrease the transcription of
enes involved in inflammation, but have endocrine and
etabolic side effects when given systemically (Barnes
nd Karin, 1997), side effects that may not occur with a
ore specific NF-kB inhibitor. Adenovirus-mediated
ransfer of the super repressor form of IkBa was shown
o inhibit NF-kB activation and proinflammatory gene
expression but also compromised the NF-kB-induced
rotection of cells from apoptosis (Bach et al., 1997;
iagkov et al., 1998; Wrighton et al., 1996). As an alter-
ative, we utilized retroviral-mediated transfer of two
ominant negative mutants of IKKg. The bicistronic AP-2
retroviral vector represents a very efficient system of
gene delivery that permits high levels of transduction
and supports long-term expression of the transgene
(Galipeau et al., 1999).
The IKKg/NEMO subunit is an essential component of
the IKK complex and constitutes a regulatory subunit that
serves to link and integrate the IKK complex to upstream
activators (Israel, 2000). The endogenous IKKg is present
as a 48/50-kDa doublet, although the role of the two
different proteins is unknown. The two dominant nega-
tive mutants of IKKg—DC-IKKg-261 and DC-IKKg-306—
both carry deletions of the C-terminal domain but retain
o
i
l
428 LE PAGE ET AL.FIG. 5. Inhibition of IkBa promoter activation in U-306 and U-261 cells. (A) Inhibition of IkBa mRNA expression. U937, U-AP2, or DC-IKKg
transduced cells were stimulated with TNFa (10 ng/ml) for 1 h or Sendai virus (80 HAU/ml) for 4 h. Total RNA (5 mg) was subjected to RNase
protection assay using the 276-nt 39 cDNA probe (Algarte et al., 1999). Labeled fragments protected from RNase digestion and corresponding
to IkBa mRNA were quantified. Similar results were obtained in two independent studies. (B) Inhibition of IkBa promoter activation. Cells were
transfected with wild-type or mutant IkBa promoter–luciferase constructs. At 16 h after transfection, cells were incubated with TNFa (10 ng/ml)
r Sendai virus (80 HAU/ml) for 10 h. Cell extracts were assayed for luciferase activity. Relative luciferase activity (expressed as fold induction)
s the ratio of luciferase activity in stimulated cells to that in unstimulated U937 cells. Transfection efficiency was normalized to that of Renilla
uciferase. Values are the mean of three independent experiments performed in duplicate. (C) Inhibition of NF-kB binding activity. Cells were
stimulated with TNFa (10 ng/ml) and Sendai virus virus (80 HAU/ml) for 1 or 6 h, respectively. The NF-kB DNA-binding activity of was determined
32by EMSA using a g- P-end-labeled IkBa kB1 probe and the position of the p50/p65 complex is indicated (Algarte et al., 1999). Similar results
were obtained in two independent studies.
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429IKKg/NEMO MUTANTS DISRUPT IKK SIGNALING AND NF-kB ACTIVATIONthe ability to bind the IKK complex, in agreement with
data showing that the amino-terminal region is respon-
sible for the association of IKKg with IKKa and IKKb
subunits (Chu et al., 1999; Mercurio et al., 1999; Ye et al.,
2000). However, in contrast to the full-length IKKg
polypeptide which forms homodimers and trimers (Roth-
warf et al., 1998; Yamaoka et al., 1998; Ye et al., 2000),
arboxy-terminal deletion abrogates the capacity of DC-
KKg to associate with endogenous full-length IKKg.
hese results indicate that deletion of the last leucine
ipper domain contributes to the dimerization of IKKg. In
support of this observation, recent experiments demon-
strate that the IKK complex undergoes oligomerization in
response to TNFa stimulation and receptor interacting
protein regulates the activity of the IKK complex through
the oligomerization of IKKg. IKKg-mediated oligomeriza-
FIG. 6. Inhibition of chemokine gene expression. (A) Inhibition of ch
timulated with TNFa (10 ng/ml) for 2 h or Sendai virus (80 HAU/ml) fo
cDNA probe (Pharmigen). Labeled fragments protected from RNase di
were normalized according to the GADPH mRNA levels and plotted a
obtained in three independent studies. (B) Inhibition of NF-kB binding a
endai virus virus (80 HAU/ml) for 1 or 6 h, respectively. The NF-kB DN
probe from the RANTES promoter and the position of the p50/p65 comtion of the IKK complex or enforced oligomerization of
any of the IKK components appears sufficient to activatethe IKK complex and the NF-kB pathway (Poyet et al.,
2000).
Overexpression of DC-IKKg mutants strongly inhibits
he TNFa- and virus-induced IKK activity, in agreement
with previous observations suggesting that the C-termi-
nal region of IKKg serves as an association domain with
upstream activators. As a consequence, DC-IKKg ex-
pression blocked NF-kB DNA binding to the IkBa pro-
moter and correlated with inhibition of IkBa gene expres-
sion in both transient transfection and RNase protection
assays. However, in stimulated U-261 and U-306 cells,
only a weak inhibition of the IkBa degradation process
was observed compared to the strong inhibition of NF-kB
DNA binding activity and NF-kB-dependent gene expres-
ion, indicating that IKK complexes containing DC-IKKg
retain some IkBa phosphorylation and degradation-re-
e mRNA expression. U937, U-AP2, or DC-IKKg transduced cells were
otal RNA (5 mg) was subjected to RNase protection assay using CK5
and corresponding to chemokine mRNA were quantified. The values
lated/unstimulated conditions in the inset table. Similar results were
on RANTES promoter. Cells were stimulated with TNFa (10 ng/ml) and
ing activity was determined by EMSA using a g-32P-end-labeled NF-kB
indicated (Lin et al., 1999).emokin
r 6 h. T
gestion
s stimu
ctivitylated activity. DC-IKKg may be implicated at a distinct
NF-kB activation step such as phosphorylation of p65
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430 LE PAGE ET AL.which enhances the affinity of p65 for specific kB-DNA
motifs and increases NF-kB transcriptional activity (Nau-
mann and Scheidereit, 1994). Interestingly, IKKb phos-
phorylates p65 in vitro and in vivo TNFa-induced phos-
horylation of p65 by IKK occurs prior to the nuclear
ranslocation of NF-kB (Mercurio et al., 1999; Sakurai et
al., 1999). The IKKg subunit may thus be indirectly in-
volved in controlling p65 phosphorylation by IKK, with
IKKg linking other components to the IKK complex in
order to amplify NF-kB activation.
We were unable to generate a stable retrovirus that
xpressed full-length IKKg, possibly because overex-
pression of IKKg causes apoptosis in the packaging cell
line (Ye et al., 2000). Clearly, the C-terminal deletion of
KKg uncoupled apoptotic activity, since the DC-IKKg
mutants were able to block NF-kB-dependent gene ac-
ivity in response to TNF or virus infection. Previous
tudies have also demonstrated that full-length IKKg,
when overexpressed in cells with functional endogenous
levels of IKKg, inhibited the expression of NF-kB-depen-
dent genes. The DC-IKKg mutants thus are not dominant
negative mutants since they retain the inhibitory function
but are no longer pro-apoptotic (Leonardi et al., 2000; Li
et al., 1999d; Ye et al., 2000; Zhang et al., 2000).
Inflammatory stimuli, such as TNFa, bacterial prod-
ucts, and viruses induce multiple pro-inflammatory
genes, including cytokines and chemokines (MIP-1, RAN-
TES, IL-1, IL-8) which are regulated in part through the
activation of NF-kB. While inflammation is essential to
innate host defense, chronic release of inflammatory
mediators such as chemokines may ultimately contribute
to the pathogenesis of allergic inflammation in patients
suffering from asthma or rheumatoid arthritis. Therefore,
the ability to attenuate the pathophysiological effects of
chemokines may ameliorate the course of chronic in-
flammatory disease. In view of the multiplicity of chemo-
kines and cytokines released at the site of inflammation,
an interesting strategy is to interfere with the signaling
pathways leading to chemokine release. Previously, in
animal models of rheumatoid arthritis (Miagkov et al.,
1998), suppression of NF-kB by either proteosome inhib-
tors or intraarticular adenoviral gene transfer of super
epressor IkBa significantly enhanced apoptosis in the
synovium of rats with experimentally induced arthritis,
suggesting that NF-kB protected the cells in the syno-
ium against apoptosis. Intraarticular administration of
F-kB decoys prevented the recurrence of arthritis in
treated joints and, unexpectedly, the severity of the ar-
thritis was also significantly reduced in the contralateral
untreated joint, indicating that beneficial systemic effects
of local suppression of NF-kB had occurred.
In a related approach to inhibition of IKK activity (May
et al., 2000), an amino-terminal a-helical region of NEMO
was shown to interact with the carboxyl terminal seg-
ment of IKKa and IKKb, (termed the NEMO binding do-
ain, NBD). Using a cell permeable NBD peptidomi-etic, association of NEMO with the IKK complex was
isrupted, resulting in the inhibition of NF-kB-dependent
ene activation. NBD peptide also decreased inflamma-
ory responses in two experimental mouse models of
cute inflammation. Ear edema induced with PMA was
educed by NBD peptide by greater than 75%, an effect
hat was as effective as dexamethasone administration.
n a mouse model of peritonitis induced by zymosan
njection, accumulation of inflammatory exudate fluids
nd migration of polymorphonuclear cells to the perito-
eum were inhibited by the administration of NBD pep-
ide or by dexamethasone. NBD thus appears to be an
ttractive target for drug development, with the potential
o block pro-inflammatory activation of the IKK complex
ithout inhibiting basal NF-kB activity.
As demonstrated in the present study, expression of
DC-IKKg mutants inhibited induction of MIP1-a, MIP1b,
ANTES, and IL-8 expression in response to viral infec-
ion or TNFa stimulation via inhibition of NF-kB DNA
binding. Moreover, preliminary results demonstrate that
overexpression of DC-IKKg does not sensitize cells to
TNFa-mediated cell death (data not shown). The ability
f DC-IKKg to “dampen” NF-kB activation and chemokine
release without completely blocking this essential path-
way or sensitizing cells to apoptosis suggests that this
approach may have therapeutic potential in inflammatory
or allergic disorders.
MATERIALS AND METHODS
Plasmid construction
The coding sequence of IKKg was amplified by PCR
nd NotI and EcoRI sites were introduced into 59- and
9-ends respectively. The cDNA fragment was cloned
nto NotI and EcoRI sites of the pCMV2 Flag vector
Sigma) in frame with the Flag tag to produce a N-
erminal tagged IKKg. DC IKKg-306 and DC IKKg-261
were generated from wild-type Flag-IKKg by digestion
using restriction sites BglII and EcoRV, respectively. Flag
DC-IKKg was excised from the pflag-CMV2-IKKg expres-
sion vector using blunted NcoI and BamHI restriction
digests and introduced into blunted XhoI and BamHI
sites of the AP-2 retroviral vector (Galipeau et al., 1999).
The fidelity of vector insert ligation was verified by se-
quencing using the Amersham sequencing kit, following
the manufacturer’s instructions.
Cell culture and retroviral transduction
Stable transfection of IKKg-AP2 into the 293GPG pack-
aging cell line (Galipeau et al., 1999) which expresses
viral structural genes under the control of a tetracycline-
regulated promoter was achieved using the lipofectin
method (Life Technologies, Inc). Stably transfected cells
were generated by cotransfection of retroviral vector and
1:25 pJ6aBleo plasmid carrying the zeocin resistance
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mented with 100 mg/ml zeocin (Life Technologies, Inc.).
Production of viral particles was achieved by culturing
293GPG packaging cells in RPMI (Life Technologies,
Inc.) medium supplemented with 5% FBS (Life Technol-
ogies, Inc.). Supernatant containing fully packaged retro-
virus was collected daily and stored at 280°C. To
achieve transduction, target cells were incubated with
500 ml of retrovirus conditioned medium with 5 mg/ml of
polybrene. The procedure was repeated for 3 consecu-
tive days. Flow cytometry analysis was performed 1
week after initial contact to verify retroviral expression as
measured by green fluorescence protein (GFP) fluores-
cence. After transduction, transduced U937 cells were
maintained in RPMI 1640 medium, supplemented with
10% FBS (Life Technologies, Inc.) and 10 mg/ml of gen-
tamicin (Schering Canada).
Immunoprecipitation and Western blot analysis
Protein samples (150 mg) were incubated overnight at
°C with specific antibodies (1 mg/ml) and 30 ml of
rotein A- or G-Sepharose (Amersham Pharmacia) was
dded for 1 h at 4°C. The precipitated proteins were
ashed with cold lysis buffer (10 mM Tris–HCl, pH 8.0, 60
M KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM
MSF, 0.2 mM sodium orthovanadate, 10 mg/ml of apro-
inin, leupeptin, and pepstatin), boiled in loading buffer,
eparated by 10% SDS–PAGE, and transferred to a nitro-
ellulose membrane (Amersham Pharmacia) under re-
rigerated conditions (40 V, 2 h). The membrane was
aturated with 5% milk/13 TBS/0.1% Tween 20. Immuno-
etection was performed by incubation for 1 h at room
emperature with specific antibody (1 mg/ml) (Santa
Cruz). The membrane was washed two times with TBS/
0.1% Tween 20 and incubated for another 1 h at room
temperature with a 1:10,000 dilution of peroxidase-con-
jugated anti-rabbit or anti-mouse IgG, as described in the
protocol of the ECL kit (NEN Life Science Products).
In vitro kinase assay
Total extracts (200 mg) were immunoprecipitated with
nti-IKKa antibody and the resulting complexes were
washed twice with lysis buffer and kinase buffer (20 mM
HEPES, pH 7.4, 10 mM MgCl2, 20 mM b-glycerophos-
hate, 50 mM NaCl, 1 mM DTT, 10 mM PNPP, 0.1 mM
thovanadate, 0.2 mM PMSF, and 5 mg/ml of aprotinin,
eupeptinin, and pepstatin). The immune complexes
ere then incubated for 30 min at 30°C in kinase buffer
ith 5 mCi ([g-32P]ATP) and 2 mg of GST-IkBa (aa 1–55) or
GST-IkBa2ND4 as substrates. With GST-IkBa2ND4, Ser
32 and 36 were mutated to alanine and contained a
deletion in the C-terminal PEST domain (Lin et al., 1996).
Proteins were denatured and separated by 10% SDS–
PAGE, and the lower part of the gel was dried and
visualized by autoradiography. The upper part of the gelwas transferred on nitrocellulose membrane for Western
blot analysis using anti-IKK-a antibody.
Electrophoretic mobility shift assay (EMSA)
Whole cell extracts were prepared and subjected to
EMSA using 32P-labeled probes corresponding to the
kB1 site of the IkBa promoter, 59-GAT CTT GGA AAT TCC
CC GA-39 (Algarte et al., 1999), or the (243 to 230)
F-kB region of the RANTES promoter, 59-ACT CCC CTT
AGG GGA TGC CCC TCA A-39 (Genin et al., 2000). Bind-
ing reactions were carried out in binding buffer (20 mM
HEPES, pH 8.0, 5% glycerol, 0.1 KCl, 0.2 mM EDTA pH 8.0,
0.2 EGTA pH 8.0, 0.5 mg poly(dIdC)) containing cell ex-
ract (10 mg) and the radiolabeled probe. The resulting
protein–DNA complexes were separated on a 5% non-
denaturating polyacrylamide gel in Tris–borate–EDTA
buffer. The gel was dried and exposed for autoradiogra-
phy.
Transfection and luciferase reporter assay
Transfections for luciferase reporter assay were car-
ried out in 293 GPG cells. A total of 1 3 106 cells were
cotransfected in 24-well plates with 1.0 mg of DNA and
200 ng of a constitutively active Renilla luciferase control
plasmid, pRL-TK (Promega), by the calcium phosphate
coprecipitation method. Cells were then washed in fresh
medium and incubated overnight at 37°C. After this time,
cells were stimulated for 10 h with TNFa (10 ng/ml),
endai virus (80 HAU/ml). Cells were then assayed for
uciferase activity in duplicate using the dual luciferase
eporter assay system (Promega). The wild-type IkBa
and the mutant kB1 promoters used in these assays
ere previously described (Algarte et al., 1999).
ibonuclease protection assay
Total RNA was prepared using the RNeasy kit from
iagen. Total RNA (5 mg) was subjected to RNase pro-
ection assay using RiboQuant CK5 human chemokine
emplate RPA kit (PharMingen, San Diego, CA) or the
reviously described IkBa antisense RNA probe (Algarte
et al., 1999) following the manufacturer’s instructions.
Total RNA was hybridized with the probe and labeled
fragments were protected from RNase digestion. The
samples were run on a 5% denaturing gel and the results
were quantified using the NIH Image 1.60 software pack-
age.
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